Catalog No.
DHC27706
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
scFv-TCR
Clonality
Monoclonal
Target
CD3E, gp100 peptide-HLA Complex, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1.06 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
9mM Citric acid monohydrate, 41mM Na2HPO4, 1% Mannitol, 5% Trehalose, 0.02% Tween 20, 2mM DTT, pH 6.5.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific fusion protein, CAS: 1874157-95-5
Clone ID
Tebentafusp
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma, PMID: 31336704
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma, PMID: 32816891
Uveal melanoma, PMID: 32273508
Immunotherapies for the Treatment of Uveal Melanoma-History and Future, PMID: 31344957
Novel Approaches to the Systemic Management of Uveal Melanoma, PMID: 32725406
Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours, PMID: 31207478
TCR Bispecific Boosts Survival in Uveal Melanoma, PMID: 33839690
Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives, PMID: 34431316
Severity and Progression of Dermatologic Adverse Events Associated with Tebentafusp: A Retrospective Multicenter Cohort Study., PMID:40513891
Non-Cutaneous Melanoma: Biology, Clinical Management, Current Therapy, and Future Directions in Treatment., PMID:40413010
[New therapeutic approaches in the neoadjuvant/adjuvant treatment of melanoma]., PMID:40407846
State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update : How to treat Metastatic Uveal Melanoma in 2025., PMID:40380030
Access to current medicines in the treatment of Turkish melanoma patients., PMID:40325969
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients., PMID:40311102
Targeted theranostic nanomedicine using targeted CT-imageable particles that release tebentafusp., PMID:40244495
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific., PMID:40239619
Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open., PMID:40233298
Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp., PMID:40174442
Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors., PMID:40138603
How we treat patients with metastatic uveal melanoma., PMID:40112696
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer., PMID:40064880
Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report., PMID:40004863
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database., PMID:39982395
Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E-Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations., PMID:39962018
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology., PMID:39721295
Prognostic Biomarkers in Evolving Melanoma Immunotherapy., PMID:39707058
The role of circulating tumor DNA in melanomas of the uveal tract., PMID:39697328
Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma., PMID:39670827
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study., PMID:39670438
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors., PMID:39647344
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma., PMID:39551602
Response to comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis"., PMID:39431664
Comment on: "Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis"., PMID:39431660
Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication., PMID:39411069
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma., PMID:39409881
Early poliosis- and vitiligo-like depigmentation as an indicator of treatment response in patients with uveal melanoma under tebentafusp therapy., PMID:39403945
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp., PMID:39402032
[Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches]., PMID:39355878
Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study., PMID:39352553
Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model., PMID:39349498
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database., PMID:39247253
Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients., PMID:39216820
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma., PMID:39204391
Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021., PMID:39184023
Exudative subretinal fluid associated with tebentafusp immunotherapy., PMID:39178911
Tailoring surveillance imaging in uveal melanoma based on individual metastatic risk., PMID:39151896
GP100 expression is variable in intensity in melanoma., PMID:39105816
Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review., PMID:39026970
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action., PMID:39019150
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis., PMID:39004419
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events., PMID:38915414
The Current State of Systemic Therapy of Metastatic Uveal Melanoma., PMID:38907174
Tebentafusp (Kimmtrak) for uveal melanoma., PMID:38905528
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma., PMID:38844408
[Side effects of dermato-oncologic therapies]., PMID:38802653
Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment., PMID:38785402
Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic., PMID:38697822
For research use only. Not for human or drug use.
